ES2082850T3 - Inmunoglobulinas preparadas geneticamente. - Google Patents

Inmunoglobulinas preparadas geneticamente.

Info

Publication number
ES2082850T3
ES2082850T3 ES90904172T ES90904172T ES2082850T3 ES 2082850 T3 ES2082850 T3 ES 2082850T3 ES 90904172 T ES90904172 T ES 90904172T ES 90904172 T ES90904172 T ES 90904172T ES 2082850 T3 ES2082850 T3 ES 2082850T3
Authority
ES
Spain
Prior art keywords
immunoglobulins
epitope
immunoglobulin
genetically
genetically prepared
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES90904172T
Other languages
English (en)
Inventor
Maurizio Zanetti
Maurizio Sollazzo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23227670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2082850(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Application granted granted Critical
Publication of ES2082850T3 publication Critical patent/ES2082850T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

INMUNOGLOBULINS QUE HAN SIDO TRAMADOS GENETICAMENTE PARA EXPRESAR UN EPITOPE PEPTIDO PREDEFINIDO EN LA REGION VARIABLE O EN EL DOMINIO DE ENLACE DEL INMUNOGLOBULIN. EL EPITOPE QUE CONTIENE INMUNOGLOBULINS ES UTIL EN EL TRATAMIENTO DE ENFERMEDADES COMO LOS DESORDENES AUTOINMUNIDAD, YA QUE AL INSERTARSE EL EPITOPE EN EL DOMINIO DE ENLACE DEL INMUNOGLOBULIN ES CAPAZ DE INDUCIR O IMPEDIR LA SENSIBILIZACION DEL HUESPED A ESTE EPITOPE.
ES90904172T 1989-02-24 1990-02-23 Inmunoglobulinas preparadas geneticamente. Expired - Lifetime ES2082850T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US31614489A 1989-02-24 1989-02-24

Publications (1)

Publication Number Publication Date
ES2082850T3 true ES2082850T3 (es) 1996-04-01

Family

ID=23227670

Family Applications (1)

Application Number Title Priority Date Filing Date
ES90904172T Expired - Lifetime ES2082850T3 (es) 1989-02-24 1990-02-23 Inmunoglobulinas preparadas geneticamente.

Country Status (9)

Country Link
US (3) US5508386A (es)
EP (1) EP0460076B1 (es)
JP (2) JP3355351B2 (es)
AT (1) ATE130765T1 (es)
CA (1) CA2047244C (es)
DE (2) DE69023900T4 (es)
DK (1) DK0460076T3 (es)
ES (1) ES2082850T3 (es)
WO (1) WO1990009804A1 (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69023900T4 (de) * 1989-02-24 1996-10-02 The Regents Of The University Of California, Berkeley, Calif. Gentechnologisch veränderte immunglobuline.
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
DK96493D0 (da) * 1993-08-26 1993-08-26 Mouritsen Og Elsner Aps Fremgangsmaade til at inducere antistofresponser mod selvproteiner og autovaccine fremstillet ved fremgangsmaaden
US5817308A (en) * 1994-02-14 1998-10-06 University Of Rochester Tolerogenic fusion proteins of immunoglobulins and methods for inducing and maintaining tolerance
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US6086875A (en) * 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
US6485726B1 (en) 1995-01-17 2002-11-26 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
ATE233102T1 (de) * 1996-05-15 2003-03-15 Altarex Inc Verfahren und zusammensetzung zur umgestaltung multi-epitopischer antigene um die immunantwort einzuleiten
US20060159688A1 (en) * 1996-05-15 2006-07-20 Ragupathy Madiyalakan Method for diagnosing efficacy of xenotypic antibody therapy
US7361346B1 (en) * 1996-05-15 2008-04-22 Altarex Corp. Therapeutic compositions that produce an immune response
US7318921B2 (en) * 1996-05-15 2008-01-15 Altarex Medical Corp. Therapeutic compositions that alter the immune response
US20080220012A1 (en) * 1996-05-15 2008-09-11 Ragupathy Madiyalakan Therapeutic Compositions that alter the immune response
US8038994B2 (en) * 1996-05-15 2011-10-18 Quest Pharmatech Inc. Combination therapy for treating disease
US6737057B1 (en) * 1997-01-07 2004-05-18 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
US20020081298A1 (en) * 1997-01-07 2002-06-27 Habib Zaghouani Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
BR9815289A (pt) * 1997-11-14 2001-12-26 Euro Celtique Sa Imunoglobulina modificada, molécula, ácidonucleico isolado, célula contendo o mesmo, animalnão-humano recombinante, composiçãofarmacêutica, composição de vacina, processospara identificar ou medir ou detectar um antìgenode câncer, um antìgeno de um agente de doençainfecciosa, um ligante, e um receptor em umaamostra a ser testada, kits para detecção de umantìgeno de câncer, de um antìgeno de um agentede doença infecciosa, de um receptor celular paraum agente de doença infecciosa, de um ligante, e deum antìgeno de câncer, processos de diagnósticoou de exame para a presença de ou umapredisposição para desenvolvimento de um câncertipificado pela presença aumentada de umantìgeno de câncer, e para a presença de umagente de doença infecciosa, processos detratamento ou de prevenção de um câncertipificado pela presença de um antìgeno de câncer,de uma doença infecciosa tipificada pela presençade um antìgeno de agente de doença infecciosa, ede uma doença causada por um agente de doençainfecciosa que se liga em um receptor celular,processos para modulação de atividade de umprimeiro membro de um par de ligação, processo deprodução de uma imunoglobulina modificada,processo de produção de um ácido nucleicocodificador de imunoglobulina modificada, e, ácidonucleico isolado
US7026446B1 (en) * 1997-12-24 2006-04-11 Diatech Pty Ltd. Bifunctional molecules
US7279462B1 (en) 1998-04-27 2007-10-09 Nevagen Llc Somatic transgene immunization and related methods
CA2350917A1 (en) * 1998-11-13 2000-05-25 Euro-Celtique, S.A. Contraceptive antibody vaccines
WO2000050455A2 (en) * 1999-02-25 2000-08-31 Tai June Yoo Antigen to systemic lupus erythematosis and diagnostic assay
CA2369616C (en) * 1999-04-27 2009-09-15 Eurogen Holding, S.A. Somatic transgene immunization and related methods
EP1246643A4 (en) 1999-10-14 2005-05-11 Jeffery A Ledbetter DNA VACCINES ENCODING ANTIGEN ASSOCIATED WITH CD40-BINDING DOMAIN
AU2001241533A1 (en) * 2000-02-15 2001-08-27 The Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
PL211872B1 (pl) * 2000-03-31 2012-07-31 Purdue Research Foundation Kompozycja farmaceutyczna
WO2003002908A1 (en) * 2000-06-26 2003-01-09 Reveo, Inc. Backlight for a liquid crystal display having high light-recycling efficiency
GB0102145D0 (en) * 2001-01-26 2001-03-14 Scancell Ltd Substances
AU2002307062A1 (en) * 2001-04-02 2002-10-15 Purdue Pharma L.P. Thrombopoietin (tpo) synthebody for stimulation of platelet production
EP1497654A4 (en) 2001-08-13 2006-06-07 Chen Swey Shen Alex IMMUNOGLOBULIN E VACCINES AND METHODS OF USE
KR20040053136A (ko) * 2001-09-28 2004-06-23 펄듀 리서치 파운데이션 리간드-면역원 공액체를 이용한 치료 방법
US20070037769A1 (en) * 2003-03-14 2007-02-15 Multicell Immunotherapeutics, Inc. Compositions and methods to treat and control tumors by loading antigen presenting cells
EP2258712A3 (en) 2002-03-15 2011-05-04 Multicell Immunotherapeutics, Inc. Compositions and Methods to Initiate or Enhance Antibody and Major-histocompatibility Class I or Class II-restricted T Cell Responses by Using Immunomodulatory, Non-coding RNA Motifs
JP2005526778A (ja) * 2002-03-15 2005-09-08 アストラル，インコーポレイテッド 免疫調節性非コードｒｎａモチーフを用いて抗体及び主要組織適合性クラスｉ拘束性又はクラスｉｉ拘束性ｔ細胞の応答を開始或いは増強させるための組成物及び方法
US8603471B2 (en) 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions for preventing the onset of type 1 diabetes
NZ536054A (en) 2002-04-09 2009-10-30 Scripps Research Inst Motif-grafted hybrid polypeptides and uses thereof
US8609091B2 (en) 2002-04-09 2013-12-17 The Curators Of The University Of Missouri Method for endocytic presentation of an immunosuppressive for the treatment of type 1 diabetes
US8603472B2 (en) 2002-04-09 2013-12-10 The Curators Of The University Of Missouri Methods and compositions reversing pre-diabetes using fusion proteins comprising a GAD peptide
US7744876B2 (en) 2002-04-09 2010-06-29 The Curators Of The University Of Missouri Methods and compositions for treatment, prevention, suppression, and/or delaying the onset of type 1 diabetes
JP2005522483A (ja) * 2002-04-11 2005-07-28 アルタレックス メディカル コーポレーション 結合剤及び腫瘍細胞をターゲティングする際のそれらの使用
JP2005532296A (ja) * 2002-04-19 2005-10-27 エンドサイト，インコーポレイテッド アジュバントにより増強される免疫療法
US20060172959A1 (en) * 2003-03-26 2006-08-03 Dan Smith Selected rna motifs to include cell death and/or apoptosis
US7696322B2 (en) * 2003-07-28 2010-04-13 Catalent Pharma Solutions, Inc. Fusion antibodies
US20060035242A1 (en) * 2004-08-13 2006-02-16 Michelitsch Melissa D Prion-specific peptide reagents
WO2006076683A2 (en) * 2005-01-13 2006-07-20 Novartis Vaccines And Diagnostics Inc. Isolation and detection of pathogenic prions
MX2007008497A (es) * 2005-01-13 2007-09-14 Novartis Vaccines & Diagnostic Ensayos inmunosorbentes enlazados a enzimas usando reactivos de peptidos especificos de prion.
US20070111237A1 (en) * 2005-09-14 2007-05-17 Maurizio Zanetti Process for identifying antigenized antibodies using ribosome cell free expression system
US8168164B2 (en) * 2006-02-03 2012-05-01 Purdue Research Foundation Targeted conjugates and radiation
EP1887084A1 (en) 2006-08-10 2008-02-13 International Investment and Patents SA Plasmids with immunological action
US8865179B2 (en) * 2008-01-26 2014-10-21 Swey-Shen Alexchen Aptameric IgE peptides in a protein scaffold as an allergy vaccine
CA2721982A1 (en) * 2008-04-30 2009-11-05 Novartis Ag Assay for pathogenic conformers
US10441649B2 (en) 2015-02-02 2019-10-15 The University Of Birmingham Targeting moiety peptide epitope complexes having a plurality of T-cell epitopes

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4694072A (en) * 1982-11-30 1987-09-15 Institut Pasteur Peptides comprising an immunogenic site of poliovirus and DNAS containing nucleotide sequences coding for these peptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4631191A (en) * 1985-06-20 1986-12-23 Biotechnology Research Partners, Ltd. Methods and compositions useful in preventing equine influenza
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL84285A (en) * 1986-10-27 1993-03-15 Int Genetic Engineering Chimeric antibody with specificity to human tumor antigen
DE69023900T4 (de) * 1989-02-24 1996-10-02 The Regents Of The University Of California, Berkeley, Calif. Gentechnologisch veränderte immunglobuline.
EP0580758A4 (en) * 1991-04-18 1995-04-05 Sinai School Medicine RECOMBINANT ANTIBODIES AGAINST HUMAN IMMUNE WEAKNESS VIRUS.

Also Published As

Publication number Publication date
JP2001190295A (ja) 2001-07-17
DE69023900T4 (de) 1996-10-02
EP0460076A1 (en) 1991-12-11
EP0460076A4 (en) 1992-08-05
WO1990009804A1 (en) 1990-09-07
JP3357890B2 (ja) 2002-12-16
CA2047244C (en) 2002-09-17
US5658762A (en) 1997-08-19
DE69023900T2 (de) 1996-07-04
US5583202A (en) 1996-12-10
JP3355351B2 (ja) 2002-12-09
DK0460076T3 (da) 1996-03-25
JPH04503605A (ja) 1992-07-02
ATE130765T1 (de) 1995-12-15
US5508386A (en) 1996-04-16
EP0460076B1 (en) 1995-11-29
DE69023900D1 (de) 1996-01-11
CA2047244A1 (en) 1990-08-25

Similar Documents

Publication Publication Date Title
ES2082850T3 (es) Inmunoglobulinas preparadas geneticamente.
ATE190496T1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
ES2084338T3 (es) Anticuerpos recombinantes especificos para el tnf alfa.
DE10199020I1 (de) Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit
DE3751470D1 (de) Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.
ATE127341T1 (de) Neue verwendung von modafinil.
ES2148332T3 (es) Procedimiento para la produccion de concentrado de inmunoglobulinas g.
ES8601699A1 (es) Un metodo para tratar un concentrado del factor viii de coagulacion de la sangre
ES8506450A1 (es) Procedimiento para higienizar o pasterizar fribrinogeno humano
DE3685633D1 (de) Behandlung von knochenstoerungen.
DE58906239D1 (de) Einrichtung zur Behandlung von Erkrankungen, insbesondere der Sehbahn.
ES2044514T3 (es) Agua de aloe, procedimiento de preparacion y composiciones que la contienen.
ES489003A0 (es) Procedimiento para el tratamiento de boruracion de piezas hechas de metal o de cermets.
DE3584560D1 (de) Arzneimittelzusammensetzung geeignet zur behandlung oder prophylaxe von herzstoerungen.
ATE82502T1 (de) Zusammensetzungen zur vorbeugung von plastikabstossung.
FI820115L (fi) Tetrahydronaftalen- och indanfoereningar
RO83214A (ro) Material metalic pentru realizarea aparatelor medicale
ES2100892T3 (es) Tratamiento de enfermedades autoinmunitarias.
DE3687692D1 (de) Geschlechtshormone zur behandlung von immun-mangel-krankheiten.
DK322583D0 (da) Middel til behandling af sar
DE69010294D1 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
DE68928752D1 (de) Zubereitungen zur verwendung bei der behandlung von psoriasis und von neuropsychiatrischen krankheiten
ES2099865T3 (es) Ciclopentanoperhidrofenantreno-17beta-(3-furil)-3-derivados y composiciones farmaceuticas que comprenden los mismos para el tratamiento de trastornos cardiovasculares.
ES2110057T3 (es) Composicion medicinal que contiene tcf-ii.
ES2061969T3 (es) Compuestos macrolidos.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 460076

Country of ref document: ES